Human papillomavirus vaccination and public health

2014 ◽  
Vol 12 (4) ◽  
pp. 180-184
Author(s):  
Louise Cadman
2019 ◽  
Vol 6 (4) ◽  
pp. 317-326
Author(s):  
Gui-Dan Tang ◽  
Gu-Qing Zeng ◽  
Bi-Xia Zhao ◽  
Yun-Li Li ◽  
Rong Wang ◽  
...  

Abstract Objectives To systematically review the knowledge attitudes and the influential factors on human papillomavirus (HPV) vaccination among Chinese women. Methods Published studies on knowledge and attitudes of HPV vaccination for preventing cervical cancer among Chinese female population were retrieved using the major Chinese and English databases. Meanwhile, handwork retrieval was also conducted and the references including in the literature were retrieved. The quality of the literature was rigorously evaluated and extracted independently by two researchers and the data were analyzed and described by review manager 5.3 (RevMan5.3) software. Results In all, 19 articles including 8 articles in Chinese and 11 in English were chosen. A total of 30,176 participants were included and the sample size ranged from 64 to 6,024. The overall awareness of HPV and HPV vaccine among Chinese women was at a low level. Chinese women generally showed poor knowledge about HPV and HPV vaccine. Acceptance of HPV vaccination among Chinese women was at a high level. Vaccination intentions were influenced by the theory of planned behavior (TPB) and measured by attitudes subjective norms and perceived behavioral control. Conclusions The health authorities may evaluate and develop TPB-based interventions to increase HPV vaccination intentions of Chinese women. HPV vaccination programs should focus on carrying out multi-level and targeted health education and developing effective public health strategies after balancing the cost and benefit of HPV vaccine program. Medical staff should play the positive role in promoting the use of HPV vaccines in China. Integration of policy and community perspectives and multi-level interventions are essential to maximize the public health benefits of HPV vaccination.


2016 ◽  
Vol 214 (6) ◽  
pp. 854-861 ◽  
Author(s):  
Suzette M. Matthijsse ◽  
Jan A. C. Hontelez ◽  
Steffie K. Naber ◽  
Kirsten Rozemeijer ◽  
Inge M. C. M. de Kok ◽  
...  

2021 ◽  
pp. 100014
Author(s):  
Jordan Birebent ◽  
Aurore Palmaro ◽  
Céline Tanios-Dulot ◽  
Damien Driot ◽  
Julie Dupouy ◽  
...  

2011 ◽  
Vol 57 (1) ◽  
pp. 149-158
Author(s):  
Abdelkader El Hasnaoui ◽  
Nadia Demarteau ◽  
Denis Granados ◽  
Baudouin Standaert ◽  
Bruno Detournay

2013 ◽  
Vol 02 (04) ◽  
pp. 193-197 ◽  
Author(s):  
Sudeep Gupta ◽  
Rajendra A. Kerkar ◽  
Rajesh Dikshit ◽  
Rajendra A. Badwe

AbstractTwo vaccines that protect against infection by some of the oncogenic human papillomavirus (HPV) subtypes have recently been licensed for use in population-based vaccination strategies in many countries. However, these products are being promoted as ‘cervical cancer vaccines’ based on inadequate data. Specifically, there remain several concerns about the duration of immunogenicity, length of follow-up of trial subjects, endpoints chosen in vaccine trials, applicability of trial results to real populations, the safety of these products, and their cost-effectiveness as public health interventions. Furthermore, it is unlikely that vaccination will obviate the need for setting up robust and cost-effective screening programs in countries like India. This article will discuss various aspects of HPV vaccination from a public health perspective, especially from the point of view of its relevance to India and other South Asian countries.


Sign in / Sign up

Export Citation Format

Share Document